Chinese Hydroxychloroquine (HCQ) Market, 2020-2024 Demand, Sales, Share, Trends, Key Players and Forecasts

Hydroxychloroquine (HCQ) is an antimalarial drug. It treats malaria by killing the parasites that cause the disease. Hydroxychloroquine was listed in the United States in 1955, and the original research drug manufacturer was Sanofi. Hydroxychloroquine has been listed in Canada, France, Germany, Australia, China, Japan and other countries, and many companies worldwide have produced generic drugs of hydroxychloroquine. The indications for hydroxychloroquine include malaria, rheumatoid arthritis, lupus erythematosus, etc.

Get Free Sample Copy of Hydroxychloroquine (HCQ) Market Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=3789346

According to CRI, in 2019, the global production volume of hydroxychloroquine was approximately 300 tons. Among them, India produced about 110 tons, ranking first. The total production volume in Europe is about 80 tons, of which Sanofi's production is about 60 tons, and Novartis's Sandoz production is about 20 tons. Hydroxychloroquine produced in Europe is mainly sold to Europe and Asia. China's production is about 55 tons, most of which are sold in China. In 2020, China exported about 20 tons of hydroxychloroquine APIs. The hydroxychloroquine preparations on the global market are basically hydroxychloroquine sulfate preparations. In 2019, the world's most important hydroxychloroquine market was the United States, which consumed approximately 90 tons of hydroxychloroquine APIs, and the main source of imports was India. India is the world's second largest market, consuming approximately 60 tons of APIs. The Chinese market consumes approximately 35 tons of APIs.

It is not fully understood how this drug works to treat lupus erythematosus or rheumatoid arthritis. However, it is believed that this drug affects how your immune system works, which may be a benefit in lupus erythematosus and rheumatoid arthritis.

On March 28, 2020, FDA issued an EUA to allow hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile (SNS) to be distributed and used for hospitalized COVID-19 patients. An EUA allows for an unapproved drug to be prescribed in limited and controlled ways during an emergency such as a pandemic.

Get 20% Discount on this Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=3789346

There is a lot of controversy over whether hydroxychloroquine can prevent, treat, or cure COVID-19, the illness caused by the novel coronavirus. Some small studies in China and Europe were initially promising, however, other studies have found that hydroxychloroquine offers no benefit or may even be harmful to patients infected with the coronavirus. There are many more studies underway, but the best available evidence suggests that hydroxychloroquine is not effective in the treatment and prevention of COVID-19, and the potential benefits of the drug do not outweigh the known and potential risks. As a result, on June 15, 2020, the FDA has revoked their earlier issue of an Emergency Use Authorization (EUA) for hydroxychloroquine.

According to CRI’s market research, as of the end of 2020, only two companies in the Chinese market have been approved for hydroxychloroquine, namely Sanofi, the original research drug manufacturer of hydroxychloroquine, and Shanghai Zhongxi Pharmaceutical Co., Ltd., a generic drug manufacturer.

In 2019, the sales value of Hydroxychloroquine reached CNY340.3 million(US$49.3 million) in China. As Shanghai Zhongxi Pharmaceutical Co., Ltd.'s hydroxychloroquine product has a certain price advantage, it has occupied a major share of the Chinese market. In 2019, based on sales value, Shanghai Zhongxi Pharmaceutical Co., Ltd.'s hydroxychloroquine accounted for 69% of the Chinese market.

As some studies have shown that hydroxychloroquine may have a certain effect on COVID-19, the demand for hydroxychloroquine in the global market will increase in 2020-2021. According to CRI’s market research, from January to August 2020, China's exports of hydroxychloroquine increased by approximately 20% year-on-year. It is expected that China's domestic hydroxychloroquine market sales will continue to grow from 2020 to 2024, and China's hydroxychloroquine export value will also continue to rise.

Direct Purchase of this Hydroxychloroquine (HCQ) Market Research Report at https://www.reportsnreports.com/purchase.aspx?name=3789346

Topics Covered:
- The impact of the COVD-19 epidemic on the hydroxychloroquine market
- Development environment of Chinese Hydroxychloroquine market
- Sales value and volume of Hydroxychloroquine in China 2015-2019
- Sales value and volume of Hydroxychloroquine in Different Regions of China 2015-2019
- Prices of Hydroxychloroquine in China 2015-2019
- Prices of Sanofi’s Hydroxychloroquine(Plaquenil) in Different Regions of China 2015-2019
- Prices of Shanghai Henlius Biotech, Inc.’s Hydroxychloroquine(Fenle) in Different Regions of China 2015-2019
- Progress of Generic Hydroxychloroquine in China
- Prospects of Chinese Hydroxychloroquine Market, 2020-2024

Table of Contents

1 Basic Concepts of Hydroxychloroquine
1.1 Indications for Hydroxychloroquine
1.2 Development History of Hydroxychloroquine in China
1.3 Governmental Approval of Hydroxychloroquine in China
1.4 The impact of the COVD-19 epidemic on the hydroxychloroquine market
2 Sales of Hydroxychloroquine in China, 2015-2019
2.1 Sales Value of Hydroxychloroquine in China 2015-2019
2.1.1 Overall Sales Value of Hydroxychloroquine in China 2015-2019
2.1.2 Sales Value of Hydroxychloroquine in Different Regions of China
2.2 Sales Volume of Hydroxychloroquine
2.2.1 Overall Sales Volume of Hydroxychloroquine in China 2015-2019
2.2.2 Sales Volume of Hydroxychloroquine in Different Regions of China
2.3 Sales of Hydroxychloroquine by Dosage Form in China
3 Major Hydroxychloroquine Manufacturers in China, 2015-2019
3.1 Market Share of Major Hydroxychloroquine Manufacturers in China
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Sanofi
3.2.1 Enterprise Profile of Sanofi
3.2.2 Sales of Sanofi's Hydroxychloroquine in China
3.3 Shanghai Zhongxi Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile of Shanghai Zhongxi Pharmaceutical Co., Ltd.
3.3.2 Sales of Shanghai Zhongxi Pharmaceutical Co., Ltd. 's Hydroxychloroquine in China
4 Prices of Hydroxychloroquine in China, 2019-2020
4.1 Average Prices of Hydroxychloroquine in China
4.1.1 Average Price of Hydroxychloroquine in China
4.1.2 Average Price of Hydroxychloroquine in Different Regions of China
4.2 Prices of Major Manufacturers' Hydroxychloroquine in China
4.2.1 Price of Sanofi's Hydroxychloroquine(Plaquenil) in China
4.2.2 Price of Shanghai Zhongxi Pharmaceutical Co., Ltd. 's Hydroxychloroquine(Fenle) in China
5 Prospects of Chinese Hydroxychloroquine Market, 2020-2024
5.1 Factors Influencing Hydroxychloroquine Development in China
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size of Hydroxychloroquine in China 2020-2024
5.3 Forecast on Competition Pattern
5.4 Export of China’s Hydroxychloroquine

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

+ 1 888 391 5441
sales@reportsandreports.com

This release was published on openPR.